Ultragenyx (RARE) announced that the Phase 3 Aspire study evaluating GTX-102 as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full maternal UBE3A gene deletion.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx assumed with a Buy at H.C. Wainwright
- Ultragenyx’s UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained
- Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
- Ultragenyx participates in a conference call with JPMorgan
- Ultragenyx price target lowered to $79 from $80 at BofA